This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Big-Cap Biotech Earnings Calm Investor Nerves (Update)

BOSTON ( TheStreet) -- The biotech relief rally appears on.

Rally may be too strong a word, but the Nasdaq Biotechnology Index (NBI) is up just under 1% Thursday morning following generally strong (or at least in line) earnings reports from Biogen Idec (BIIB), Alexion Pharmaceuticals (ALXN) and Celgene (CELG). These big-cap biotech bellwethers are helping to ease some of the agita caused by Amgen's (AMGN) low-quality earnings report on Tuesday night.

The NBI fell 3% Wednesday following Amgen's poor performance, stoking fears that the biotech sector, riding a wave of all-time high stock prices, may be in for a correction.

Investors were hoping for positive earnings news today to allay those concerns, and for the most part, the big-cap biotechs delivered. Only Celgene shares are down marginally in early trading on weaker-than-expected sales of its multiple myeloma drug Revlimid.

Biogen adjusted earnings in the March quarter rose 43% to $1.97 compared to the year-ago period. Net income rose 39% year-over-year to $469 million. Analysts were expecting adjusted earnings of $1.63 per share.

A one-time tax adjustment benefit of 17 cents per share added gusto to Biogen's first-quarter earnings, but taken away, the company still beat Street expectations.

Revenue for the quarter totaled $1.41 billion, in-line with analyst expectations.

Biogen raised its financial outlook for the year, now expecting adjusted earnings in the range of $7.80-$7.90 per share against current consensus of $7.86 per share. Revenue growth for the year is expected to be approximately 16-18%, the company said.

On a conference call, Biogen said it was "encouraged" by the early interest from doctors and patients in its newly launched multiple sclerosis pill Tecfidera. The company declined to provide any specific metrics about the commercial launch.

Alexion also "beat and raise" for the first quarter, posting adjusted earnings of 65 cents per share, or 4 cents per share better than expectations. Revenue for the March quarter totaled $338.9 million, slightly ahead of the Street's $336.5 million forecast.

Alexion raised 2013 revenue guidance to $1.5 to $1.52 billion, essentially in line with current consensus. The company expects adjusted earnings in the range of $2.87-$2.97 per share versus current consensus of $2.90 per share.

Celgene posted first quarter adjusted earnings of $1.37, two cents per share better than expectations but assisted by tax benefit. Total revenue for the quarter was $1.46 billion, just shy of the $1.47 billion consensus estimate. Sales of Celgene's multiple myeloma drug Revlimid totaled $1.003 billion in the quarter, a touch weaker than expectations of $1.008 billion.

Celgene re-affirmed prior revenue guidance for the year, which may disappoint some investors who hoped for more. The company did raise guidance for adjusted earnings to $5.55-$5.65 per share, although current consensus is already at $5.70 per share.

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,173.78 -105.96 -0.61%
S&P 500 1,992.17 -18.23 -0.91%
NASDAQ 4,515.0960 -64.6930 -1.41%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs